THE EFFECT OF INCREASING THE TREATMENT TIME BEYOND 3 WEEKS ON THE CONTROL OF T2 AND T3 LARYNGEAL-CANCER USING RADIOTHERAPY

被引:86
作者
SLEVIN, NJ
HENDRY, JH
ROBERTS, SA
AGRENCRONQVIST, A
机构
[1] CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,DEPT RADIOTHERAPY,MANCHESTER M20 9BX,LANCS,ENGLAND
[2] CHRISTIE HOSP TRUST,NATL HLTH SERV,DEPT EXPTL RADIAT ONCOL,MANCHESTER M20 9BX,ENGLAND
[3] CHRISTIE HOSP,NATL HLTH SERV,PATERSON INST CANC RES,DEPT BIOMATH & COMP,MANCHESTER M20 9BX,ENGLAND
关键词
TREATMENT TIME; T2 AND T3; CONTROL OF LARYNGEAL CANCER;
D O I
10.1016/0167-8140(92)90226-K
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Local control of cancer by radiotherapy may be prejudiced by accelerated tumour clonogen repopulation particularly during protracted treatment schedules. A series of 496 cases of T2 and T3 larynx cancer treated here by radiotherapy has been studied to examine the impact on local control of treatment durations ranging from 9 to 41 days. Data were analysed using a linear-quadratic formulation describing the fractionation sensitivity, with the incorporation of a parameter relating to treatment time. Using combined T2 and T3 data, the increase in dose required to maintain a constant local control (the time factor) was between 0.5 and 0.6 Gy per day. These values are similar to those reported for 4 weeks or more in the literature. Also, the calculated dose to control 50% of tumours, given over the standard Christie duration of 21 days, was on the line projected back from literature data over 28-66 days. The present data are consistent with the presence of such a time factor following a lag phase of not more than 3 weeks after starting radiotherapy. Hence, further consideration should be given to using shorter overall treatment times in radiotherapy for head and neck cancer.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 17 条
  • [1] NEW OPTIONS IN DIRECT ANALYSIS OF DOSE-RESPONSE DATA
    BENTZEN, SM
    THAMES, HD
    TUCKER, SL
    SMITH, C
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1990, 57 (01) : 221 - 225
  • [2] CLINICAL RADIOBIOLOGY OF SQUAMOUS-CELL CARCINOMA OF THE OROPHARYNX
    BENTZEN, SM
    JOHANSEN, LV
    OVERGAARD, J
    THAMES, HD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06): : 1197 - 1206
  • [3] CLINICAL-EVIDENCE FOR TUMOR CLONOGEN REGENERATION - INTERPRETATIONS OF THE DATA
    BENTZEN, SM
    THAMES, HD
    [J]. RADIOTHERAPY AND ONCOLOGY, 1991, 22 (03) : 161 - 166
  • [4] BUDIHNA M, 1980, STRAHLENTHER ONKOL, V156, P402
  • [5] CONTINUOUS, HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY (CHART)
    DISCHE, S
    SAUNDERS, MI
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (03) : 325 - 326
  • [6] DOSE FRACTIONATION AND REGENERATION IN RADIOTHERAPY FOR CANCER OF THE ORAL CAVITY AND OROPHARYNX - TUMOR DOSE-RESPONSE AND REPOPULATION
    MACIEJEWSKI, B
    WITHERS, HR
    TAYLOR, JMG
    HLINIAK, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (03): : 831 - 843
  • [7] THE INFLUENCE OF THE NUMBER OF FRACTIONS AND OF OVERALL TREATMENT TIME ON LOCAL-CONTROL AND LATE COMPLICATION RATE IN SQUAMOUS-CELL CARCINOMA OF THE LARYNX
    MACIEJEWSKI, B
    PREUSSBAYER, G
    TROTT, KR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (03): : 321 - 328
  • [8] COMPARISON OF CONVENTIONAL AND SPLIT-COURSE RADIOTHERAPY AS PRIMARY-TREATMENT IN CARCINOMA OF THE LARYNX
    OVERGAARD, J
    HJELMHANSEN, M
    JOHANSEN, LV
    ANDERSEN, AP
    [J]. ACTA ONCOLOGICA, 1988, 27 (02) : 147 - 152
  • [9] SLEVIN NJ, 1992, IN PRESS INT J RAD O
  • [10] STEEPNESS OF DOSE-RESPONSE CURVE BOTH FOR TUMOR CURE AND NORMAL TISSUE INJURY
    STEWART, JG
    JACKSON, AW
    [J]. LARYNGOSCOPE, 1975, 85 (07) : 1107 - 1111